Skandinaviska Enskilda Banken AB publ lowered its position in shares of Becton Dickinson and Co (NYSE:BDX) by 3.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,391 shares of the medical instruments supplier’s stock after selling 1,400 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Becton Dickinson and were worth $11,847,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Acropolis Investment Management LLC purchased a new position in Becton Dickinson and during the third quarter valued at approximately $101,000. Almanack Investment Partners LLC. purchased a new position in Becton Dickinson and during the second quarter valued at approximately $105,000. Truvestments Capital LLC purchased a new position in Becton Dickinson and during the third quarter valued at approximately $105,000. Bartlett & Co. LLC lifted its holdings in Becton Dickinson and by 2,900.0% during the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 435 shares in the last quarter. Finally, Bridgeworth LLC purchased a new position in Becton Dickinson and during the second quarter valued at approximately $131,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director Timothy M. Ring sold 42,000 shares of the business’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the transaction, the director now owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP James C. Lim sold 5,189 shares of the business’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the completion of the transaction, the executive vice president now directly owns 13,318 shares in the company, valued at approximately $3,227,750.48. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by insiders.
Several equities analysts have weighed in on BDX shares. Morgan Stanley lifted their price target on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. Wells Fargo & Co lifted their price target on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Barclays started coverage on shares of Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 price target on the stock. Royal Bank of Canada reaffirmed a “hold” rating and set a $248.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Finally, KeyCorp reaffirmed a “buy” rating and set a $264.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $254.07.
BDX stock opened at $243.26 on Friday. Becton Dickinson and Co has a one year low of $209.91 and a one year high of $265.87. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95. The firm has a market capitalization of $63.38 billion, a PE ratio of 22.09, a P/E/G ratio of 1.46 and a beta of 1.19.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, hitting the consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The firm had revenue of $4.40 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the previous year, the firm earned $2.40 earnings per share. The company’s quarterly revenue was up 39.0% compared to the same quarter last year. On average, equities research analysts predict that Becton Dickinson and Co will post 12.2 EPS for the current year.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.